Literature DB >> 5917091

Dealkylation and loss of capacity for reactivation of cholinesterase inhibited by sarin.

L W Harris, J H Fleisher, J Clark, W J Cliff.   

Abstract

Inhibition of rat brain acetylcholinesterase by (32)P-sarin in vivo results initially in (32)P-isopropylmethylphosphonylated enzyme. The percentage of inhibited enzyme that could not be reactivated by pyridinium aldoxime methochloride (aged enzyme) approximated the amount of radioactivity identified as (32)P-methylphosphonate. The (32)P-isopropyl methylphosphonate not released fromthe inhibited enzyme by the oxime accounted for 51 +/- 10 percent ( standard deviation) of the radioactivity fixed to brain tissue. It showed no correlation with aging and was probably bound to sites other than acetylcholinesterase.

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5917091     DOI: 10.1126/science.154.3747.404

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  10 in total

1.  Resolving pathways of interaction of mipafox and a sarin analog with human acetylcholinesterase by kinetics, mass spectrometry and molecular modeling approaches.

Authors:  I Mangas; P Taylor; E Vilanova; J Estévez; T C C França; E Komives; Z Radić
Journal:  Arch Toxicol       Date:  2015-03-06       Impact factor: 5.153

Review 2.  Butyrylcholinesterase for protection from organophosphorus poisons: catalytic complexities and hysteretic behavior.

Authors:  Patrick Masson; Oksana Lockridge
Journal:  Arch Biochem Biophys       Date:  2009-12-11       Impact factor: 4.013

3.  Active-site determinations on forms of mammalian brain and eel acetylcholinesterase.

Authors:  M A Gordon; S L Chan; A J Trevor
Journal:  Biochem J       Date:  1976-07-01       Impact factor: 3.857

4.  Crystal structures of brain group-VIII phospholipase A2 in nonaged complexes with the organophosphorus nerve agents soman and sarin.

Authors:  Todd M Epstein; Uttamkumar Samanta; Stephen D Kirby; Douglas M Cerasoli; Brian J Bahnson
Journal:  Biochemistry       Date:  2009-04-21       Impact factor: 3.162

5.  Aging of phosphylated human acetylcholinesterase: catalytic processes mediated by aromatic and polar residues of the active centre.

Authors:  A Shafferman; A Ordentlich; D Barak; D Stein; N Ariel; B Velan
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

6.  Crystal structures of human group-VIIA phospholipase A2 inhibited by organophosphorus nerve agents exhibit non-aged complexes.

Authors:  Uttamkumar Samanta; Stephen D Kirby; Prabhavathi Srinivasan; Douglas M Cerasoli; Brian J Bahnson
Journal:  Biochem Pharmacol       Date:  2009-04-24       Impact factor: 5.858

7.  Structure of a prereaction complex between the nerve agent sarin, its biological target acetylcholinesterase, and the antidote HI-6.

Authors:  Anders Allgardsson; Lotta Berg; Christine Akfur; Andreas Hörnberg; Franz Worek; Anna Linusson; Fredrik J Ekström
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-02       Impact factor: 11.205

8.  Kinetic analysis of oxime-assisted reactivation of human, Guinea pig, and rat acetylcholinesterase inhibited by the organophosphorus pesticide metabolite phorate oxon (PHO).

Authors:  Robert A Moyer; Kevin G McGarry; Michael C Babin; Gennady E Platoff; David A Jett; David T Yeung
Journal:  Pestic Biochem Physiol       Date:  2018-01-31       Impact factor: 3.963

9.  Identification of human butyrylcholinesterase organophosphate-resistant variants through a novel mammalian enzyme functional screen.

Authors:  Jun Zhang; Sigeng Chen; Erik C Ralph; Mary Dwyer; John R Cashman
Journal:  J Pharmacol Exp Ther       Date:  2012-09-06       Impact factor: 4.030

10.  Structure of HI-6*sarin-acetylcholinesterase determined by X-ray crystallography and molecular dynamics simulation: reactivator mechanism and design.

Authors:  Fredrik Ekström; Andreas Hörnberg; Elisabet Artursson; Lars-Gunnar Hammarström; Gunter Schneider; Yuan-Ping Pang
Journal:  PLoS One       Date:  2009-06-18       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.